Try a new search

Format these results:

Searched for:

in-biosketch:true

person:chinil01

Total Results:

223


Safely Navigating the MR-Linac: A New Risk Framework for Prostate SBRT Patients with Cardiac Devices

Cooney, Jeffrey D; Gambino, Hannibal; Lee, Deborah; Amodio, Nicholas; Stojanovska, Jadranka; Chen, Ting; Wang, Hesheng; Lee, Sangkyu; Lu, Siming; Galavis, Paulina; Colangelo, Nicholas; McCarthy, Allison; Barbee, David; Vargas, Hebert Alberto; Chinitz, Larry A; Zelefsky, Michael J
PURPOSE/OBJECTIVE:Prostate stereotactic body radiation therapy (SBRT) on a 1.5-T magnetic resonance imaging (MRI) linear accelerator (MR-linac) combines high-contrast intrafraction imaging with online adaptive replanning and enables focal dose intensification. Patients with cardiac implantable electronic devices (CIEDs) nonetheless face barriers to MR-guided radiotherapy (MRgRT), because existing guidance addresses diagnostic MRI and radiotherapy exposures separately and does not specify fraction-level requirements for their combination. We developed and implemented a framework integrating both domains in one operational pathway. METHODS:A multidisciplinary group synthesized diagnostic MRI, radiotherapy, and MR-linac safety evidence into a dual-axis risk model. The MRI/CIED axis is keyed to device exposure (generator-lead configuration, manufacturer conditions, and sequence-level radiofrequency and gradient compliance) rather than anatomic field of view. The radiotherapy (RT)/CIED axis stratifies neutron production, cumulative generator dose, generator-to-field geometry, and pacing dependence. A failure mode and effects analysis translated high-priority scenarios into hold points and role assignments; the pathway is implemented prospectively for CIED patients on a 1.5-T MR-linac. RESULTS:The two axes intersect in a matrix assigning every patient to one of six classes: LOW, LOW/INTERMEDIATE, INTERMEDIATE, INTERMEDIATE/HIGH, HIGH, or HOLD. Each class specifies monitoring, consent, interrogation, programming, personnel, and platform requirements. These are implemented through a day-of-treatment workflow with named role ownership and sequential hold points aligned with the 2026 American College of Radiology Manual on MR Safety. Two determinations override the matrix: MR-hold defers MRgRT irrespective of radiotherapy category, and RT-high defaults to computed tomography-guided radiotherapy. CONCLUSIONS:By unifying MRI- and radiotherapy-specific device risks, the dual-axis framework converts categorical CIED exclusion into a graded, prospectively assigned disposition and makes every decision auditable. It is in prospective clinical use and offers appropriately selected patients a conservative route to MRgRT and the documentation from which multi-institutional validation can be built.
PMID: 43033910
ISSN: 1879-8519
CID: 6075961

1-Year Safety and Effectiveness of a Next-Generation Dual-Seal Left Atrial Appendage Occluder

Lakkireddy, Dhanunjaya; Makkar, Akash; Alkhouli, Mohamad; Freixa, Xavier; Manoukian, George; Agarwal, Himanshu; Abuissa, Hussam; Awad, Khaled; Cuoco, Frank; Dohadwala, Mustafa; Ellis, Christopher R; Shah, Dipak; De Backer, Ole; Chinitz, Larry; Nielsen-Kudsk, Jens Erik; Horton, Rodney P; Schmidt, Boris; Natale, Andrea; Reddy, Vivek Y; Sabir, Sajjad A; Weiler, Courtney; Nair, Devi; ,
BACKGROUND:Left atrial appendage occlusion (LAAO) is a stroke prevention alternative for patients with atrial fibrillation (AF) intolerant to long-term oral anticoagulation (OAC). The next-generation dual-seal device was designed to improve operator ease of use while maintaining effective LAAO of the predicate device. OBJECTIVES/OBJECTIVE:The purpose of this analysis was to evaluate the safety and effectiveness of a next-generation device through 1 year. METHODS:VERITAS is a single-arm, prospective, global, multicenter study. Patients with nonvalvular AF with an increased thromboembolism risk seeking a nonpharmacologic alternative to OAC were enrolled. One-year descriptive endpoints are provided, including mortality, neurological events, major bleeding, and device-related complications. One-year cardiac imaging was assessed for peridevice leak and device-related thrombus (DRT). RESULTS:Complete left atrial appendage (LAA) closure (0 mm leak) was observed in 91.1% (95% CI: 87.9%-93.7%) of patients by either transesophageal echocardiography (TEE) or cardiac computed tomography and 96.3% (95% CI: 93.2%-98.2%) by TEE alone. The cumulative DRT rate was 3.3% (95% CI: 2.0%-5.3%) with only 0.4% (95% CI: 0.1%-1.5%) deemed clinically relevant. One-year key clinical outcome rates are as follows: all-cause mortality: 3.9% (95% CI: 2.4%-6.3%); cardiovascular mortality: 1.9% (95% CI: 0.9%-3.8%); major bleeding: 6.6% (95% CI: 4.5%-9.2%); ischemic stroke or systemic embolism: 1.8% (95% CI: 0.8%-3.3%); pericardial effusion requiring intervention: 0.9% (95% CI: 0.3%-2.1%). No (0%) device embolization occurred. Median follow-up was 365 days (IQR: 349-380 days). CONCLUSIONS:The VERITAS study results support the 1-year safety and effectiveness of the next-generation device. (Abbott Medical-VERITAS Study; NCT06707688).
PMID: 42969901
ISSN: 1876-7605
CID: 6075432

Multi-modal AI: Integrating electrocardiography with molecular biomarkers for noninvasive detection of cardiac allograft rejection

Chen, K; Koesmahargyo, V; Ronan, R; Barbhaiya, C R; Bernstein, S A; Kushnir, A; Garber, L; Yang, F; Aizer, A; Reyentovich, A; Chinitz, L A; Goldberg, R I; Jankelson, L
UNLABELLED:Noninvasive rejection biomarkers (AlloMap, AlloSure) demonstrate high negative predictive value but positive predictive values of only 10-30%, driving avoidable endomyocardial biopsies. We developed a multi-modal AI model integrating electrocardiography with molecular biomarkers in 389 heart transplant recipients (5338 ECG-biopsy pairs), performing the first head-to-head comparison of AI-ECG, AlloMap, AlloSure, and their integration against biopsy-proven rejection. Individual modalities showed modest discrimination (AI-ECG AUC 0.65; AlloSure 0.67; AlloMap 0.56), while combining biomarkers alone did not improve performance (AUC 0.65). In the multi-modal test subset of ECGs (n=38, 2 rejection events), the integrated model achieved AUC 0.81 with 100% specificity (0/36 false positives) and 97% negative predictive value, eliminating all 19 false-positive combined-biomarker referrals. These hypothesis-generating results support prospective multi-center validation to determine whether requiring concordance across electrical and biomarker signals reduces unnecessary biopsies while preserving high negative predictive value. BACKGROUND/UNASSIGNED:Noninvasive rejection biomarkers (AlloMap gene-expression profiling (GEP); AlloSure donor-derived cell-free DNA (dd-cfDNA)) deliver high negative predictive value but positive predictive values of only 10-30%, driving avoidable endomyocardial biopsies. Each biomarker interrogates a single biological compartment. Whether integrating AI-enabled electrocardiography (AI-ECG) with these molecular assays improves specificity has not been tested. METHODS/UNASSIGNED:We retrospectively assembled 5338 unique ECG-endomyocardial-biopsy pairs from 389 adult heart transplant recipients at a single center (2018-2024). A ResNet-18 convolutional neural network was trained on 8-lead ECG waveforms with clinical covariates. In the 340-patient subset with same encounter AlloMap and AlloSure testing (405 ECG-biomarker-biopsy triplets), an integrated model fused the ECG embedding with biomarker values via late concatenation. We performed the first head-to-head, same-cohort comparison of AI-ECG, AlloMap, AlloSure, and their integration against biopsy-proven rejection (ISHLT ≥2R ACR or pAMR ≥2). Discrimination was evaluated with bootstrap 95% confidence intervals. RESULTS/UNASSIGNED:Individual modalities showed modest discrimination (AI-ECG AUC 0.65, 95% CI 0.58-0.72; AlloSure 0.67, 0.56-0.78; AlloMap 0.56, 0.46-0.67); combining biomarkers alone did not improve performance (AUC 0.65). In the multi-modal test subset (n=38 ECG-biopsy pairs, 2 rejection events), the integrated model achieved AUC 0.81 (0.50-1.00), 100% specificity (36/36; Clopper-Pearson 90-100%), and 97% NPV. At the same NPV threshold, all 19 false-positive combined-biomarker referrals in this subset would have been avoided, though this estimate reflects a single operating point in a small sample. AUC gains over single modalities did not reach statistical significance (DeLong p=0.31-0.34) given the limited event count. CONCLUSIONS/UNASSIGNED:A multi-modal AI model that requires concordance across electrical, immune-transcriptional, and donor-DNA signals showed numerically higher specificity for cardiac allograft rejection than any single modality, although the corresponding AUC differences did not reach statistical significance. These hypothesis-generating findings suggest that cross-compartment concordance may help discriminate true rejection from biomarker noise, but the small multi-modal test set precludes definitive conclusions; a pre-specified prospective multi-center trial powered for ≥50 rejection events is the necessary next step to test this hypothesis.
PMCID:13718866
PMID: 42960308
ISSN: 2950-1334
CID: 6074805

Leadless Pacemaker Implant Location as a Predictor of Pacing Induced Cardiomyopathy

Kushnir, Alexander; Aboelatta, Mones; Donnino, Robert; Holmes, Douglas; Barbhaiya, Chirag R; Bernstein, Scott; Jankelson, Lior; Aizer, Anthony; Garber, Leonid; Chinitz, Larry A
BACKGROUND:Leadless pacemakers (LPs) avoid the lead- and pocket-related complications of transvenous systems, but they pace exclusively from the right ventricle (RV), and chronic RV pacing carries a recognized risk of pacing-induced cardiomyopathy (PICM). Whether implant location within the RV, a potentially modifiable factor, contributes to this risk has not been established. METHODS:Patients undergoing LP implantation with ≥50% RV pacing, pre-and post-procedural echocardiograms, and post-implant 3-dimensional radiographic imaging were included. All implants targeted the RV septum per manufacturer recommendation. PICM was defined as ≥10% decline in left ventricular ejection fraction (LVEF) to <50% without alternative cause. RESULTS:PICM developed in 20/81 patients (24.7%), with LVEF declining from 61±8% to 37±9%. Post-implant 3-dimensional radiographic imaging demonstrated inadvertent free wall implantation in 15/20 patients who developed PICM (75%) compared with 8/61 patients who did not (13%; P <0.001). Paced QRS duration was wider in patients with PICM than in those without (186±19 vs 155±13 ms, P <0.001) and discriminated free wall from non-free wall implantation with an area under the receiver operating characteristic curve (AUC) of 0.85; a QRS duration of 172 ms provided optimal discrimination. Baseline LVEF, baseline QRS duration, and comorbidity burden did not differ between groups. CONCLUSIONS:Inadvertent free wall LP implantation is strongly associated with the subsequent development of PICM. Paced QRS duration is a readily available surrogate for implant location, and targeting a paced QRS duration below approximately 172 ms at the time of implant may serve as a practical, non-invasive check on appropriate septal placement.
PMID: 42745207
ISSN: 1540-8159
CID: 6072899

Elongated Channels Between Surgically Excluded LAA and LA: Detected by CTA But Missed by TEE [Case Report]

Asachi, Parsa; Vainrib, Alan; Loulmet, Didier F; Hage, Ali; Aizer, Anthony; Chinitz, Larry A; Ro, Richard; Saric, Muhamed
BACKGROUND:Systematic left atrial appendage (LAA) exclusion during mitral valve surgery reduces thromboembolic risk in patients with pre- or postoperative atrial fibrillation. Rare residual LAA-left atrial (LA) communications may occasionally occur after surgical exclusion and increase thromboembolic risk, particularly in patients not receiving anticoagulation. CASE SERIES/METHODS:Among more than 2,000 robotic mitral valve surgeries performed at NYU Langone Health from 2010 to 2025, LAA closure with LA posterior wall plication was performed using a continuous back-and-forth suture technique. We identified 4 patients with elongated residual LAA-LA communications that were occult on transesophageal echocardiography (TEE) but clearly visualized by cardiac computed tomography angiography (CCTA). TEE demonstrated persistent echolucency and color Doppler flow within the excluded LAA without a visible communication entrance. A tubular channel extending from the LAA, termed the "panhandle sign," was consistently observed. CCTA identified the communication orifices and guided successful transcatheter vascular plug closure. CONCLUSIONS:Rare elongated residual LAA-LA communications may be missed on routine TEE after LAA exclusion with LA plication. Persistent LAA flow and echolucency should prompt CCTA to detect occult communications and guide percutaneous closure. The "panhandle sign" may represent an imaging marker specific to our institutional extended-suture technique that facilitates earlier recognition.
PMID: 42684242
ISSN: 2666-0849
CID: 6071966

Safety and Effectiveness of a Novel Dual-Energy Radiofrequency/Pulsed Field Ablation Catheter: 12 Month Results of the FlexPulse Study

Hussein, Ayman A; Rackauskas, Gediminas; Sundaram, Sri; Piccini, Jonathan P; Roithinger, Franz Xaver; Tung, Patricia; Osorio, Jose; Colley, B Judson; Siddiqui, Usman R; Lakkireddy, Dhanunjaya R; Chinitz, Larry A; Hyman, Matthew C; Zitella Verbick, Laura; Dirckx, Nick; Woods, Virginia; Lo, Monica; ,
BACKGROUND AND AIMS/OBJECTIVE:Pulsed field (PF) ablation is increasingly used to treat paroxysmal atrial fibrillation (PAF). FlexPulse (NCT06676072) was conducted to evaluate safety and effectiveness of a novel dual-energy, flexible-tip focal ablation catheter with radiofrequency and PF for treatment of symptomatic, drug-refractory PAF. METHODS:FlexPulse was a global, prospective, single arm, multicentre study. The ablation procedures targeted pulmonary vein isolation (PVI) and adjunctive ablation at operators' discretion. The primary safety endpoint was occurrence of pre-defined safety events within 7-days of any ablation procedure. The primary effectiveness endpoint was freedom from a composite of recurrent AF/atrial tachycardia/atrial flutter, repeat procedure, new use or escalation of class I/III AAD, and/or cardioversion through 12-months. RESULTS:Overall, 180 subjects underwent PAF ablation. Successful PVI was achieved in all participants. Additional non-PV ablations were performed in 37.2% (67/180) of subjects. The primary safety endpoint event rate was 1.7%. The primary effectiveness endpoint was 74.6% at 12-months, and freedom from documented AF/AFL/AT recurrence was 77.4% (92.6% without weekly transtelephonic monitoring). In 15 subjects who underwent repeat ablation after the blanking period, remapping indicated that 79.7% (47/59) of the PVs were durably isolated from the index procedures. Retrospective analysis found that workflows with PFA Index (PI) ≥30 and AutoMark distance up to 6 mm target had a 12-month freedom from AF/AFL/AT of 84.6%. CONCLUSIONS:In this trial, ablation with TactiFlex Duo in patients with symptomatic, drug-refractory PAF was safe and effective.
PMID: 42667242
ISSN: 1532-2092
CID: 6071859

Pulmonary Vein Isolation (PVI) Versus PVI With Posterior Wall Isolation With PFA for Paroxysmal Atrial Fibrillation

Junarta, Joey; Wang, Angela; Reynolds, Eli; Hatzimemos, Aristides; Patel, Pooja; Shields, Danielle; Yang, Felix; Barbhaiya, Chirag R; Jankelson, Lior; Holmes, Douglas; Kushnir, Alexander; Garber, Leonid; Bernstein, Scott A; Park, David S; Chinitz, Larry A; Aizer, Anthony
BACKGROUND:The value of additional lesion sets beyond pulmonary vein isolation (PVI) for atrial fibrillation (AF) ablation is unclear. However, existing studies evaluated the utility of substrate modification with conventional energy sources. There is limited data evaluating PVI with posterior wall isolation (PWI) using pulsed field ablation (PFA). METHODS:We studied consecutive cases of patients with paroxysmal AF undergoing first-time ablation with PFA between May 6, 2024 and March 10, 2025. Procedural data collected included the number of PFA applications administered, total procedure time, and major periprocedural complications. Clinical data collected included atrial tachyarrhythmia (ATA) recurrence, stroke, and major bleeding at 1-year follow-up. Outcomes were compared in patients undergoing PVI alone versus PVI plus PWI. RESULTS:A total of 249 patients were included in this study (104 PVI alone, 145 PVI plus PWI). There was no difference in ATA recurrence by Kaplan-Meier survival analysis comparing PVI alone versus PVI plus PWI (log rank test p = 0.89). When comparing PVI alone versus PVI plus PWI, there was no difference in ATA recurrence at 1 year (16% vs. 16%; p = 0.92), AF burden on continuous monitoring (2% vs. 2%; p = 0.81), total procedure time (114 vs. 107 min; p = 0.14), or major periprocedural complications (0 vs. 3; p = 0.14). CONCLUSION/CONCLUSIONS:PFA for paroxysmal AF with PVI alone or PVI plus PWI produces similar sinus rhythm maintenance without affecting procedure times or complication rates.
PMID: 42631424
ISSN: 1540-8159
CID: 6071528

The Utility of Higher Pulsed Field Ablation Applications for Atrial Fibrillation Ablation

Junarta, Joey; Reynolds, Eli; Wang, Angela; Hatzimemos, Aristides; Patel, Pooja; Shields, Danielle; Yang, Felix; Barbhaiya, Chirag R; Jankelson, Lior; Holmes, Douglas; Kushnir, Alexander; Garber, Leonid; Bernstein, Scott A; Park, David S; Chinitz, Larry A; Aizer, Anthony
BACKGROUND:The optimal number of pulsed field ablation (PFA) applications during atrial fibrillation (AF) ablation is unclear. We hypothesized that the number of PFA applications would predict atrial tachyarrhythmia (ATA) recurrence rates. OBJECTIVE:To determine whether higher numbers of PFA applications would decrease ATA recurrence rates. METHODS:We studied cases of patients with AF undergoing first-time ablation with PFA between 5/6/24 and 10/7/24. All patients underwent pulmonary vein and posterior wall isolation. The primary outcome was ATA recurrence. Additional outcomes included stroke, post-procedural acute kidney injury (AKI), total procedure time, and major periprocedural complications. Univariable and multivariable analyses were performed to determine if the number of PFA applications predicted ATA recurrence. RESULTS:In a cohort consisting of 177 patients, univariable and multivariable analysis showed that the number of PFA applications split at the smallest quartile (< 57 applications) versus the largest three quartiles (≥ 57 applications) was the strongest predictor of ATA recurrence (p = 0.03). ATA recurrence at 1 year (29% vs. 8%; p < 0.01) and AF burden on continuous monitor (4% vs. 0%; p < 0.01) was higher with the standard (< 57 applications) vs higher (≥ 57 applications) PFA dose groups. When comparing the standard versus higher PFA dose groups, there was no difference in total procedure time (106 vs. 107 min; p = 0.77), major periprocedural complications (0% vs. 2%; p = 0.33), or post-procedural AKI (2% vs. 2%; p = 0.69). CONCLUSION/CONCLUSIONS:Increasing number of PFA applications is associated with reduced ATA recurrence. A higher number of PFA applications may decrease ATA recurrence without affecting procedure times or complication rate.
PMCID:13372387
PMID: 42189098
ISSN: 1540-8167
CID: 6066212

Early Capture Threshold Dynamics Following Helix-Fixation Atrial Leadless Pacemaker Implantation

Altman, Erik J; Bharbayia, Chirag; Bender, Seth; Parekh, Sameer; Arnedo, Jonathan; Undavia, Manish; Ibrahim, Basseima; Chinitz, Larry; Spinelli, Michael
PMID: 42385963
ISSN: 1556-3871
CID: 6063212

Accuracy of a Deep Learning Model in Intracardiac Echocardiography

Nair, Devi; Winterfield, Jeffrey; Hsu, Jonathan C; Gopinathannair, Rakesh; Chinitz, Larry; Pothineni, Naga Venkata K; Han, Frederick T; Dhakal, Bishnu P; Barbhaiya, Chirag; Dave, Amish S; Garcia, Fermin; Hyman, Matthew C; Dahlen, Travis; Tanouye, Kristi; Yao, Jason; Pawar, Shubhadarshini; Buckland, Judith; Gilgur, Anna; Elspas, Raphael; Gupta, Aakriti; Sandler, Roman A; Sokol, Joseph Z
BACKGROUND:Intracardiac echocardiography (ICE) is widely used during electrophysiology and structural heart procedures; however, image interpretation remains operator-dependent and procedural views are not standardized. Although artificial intelligence has been increasingly applied to transthoracic and transesophageal echocardiography, applications to ICE remain limited. OBJECTIVES/OBJECTIVE:The objective of the study was to develop and evaluate Auto-Contour, a deep-learning pipeline for multistructure semantic segmentation of ICE anatomy and assess its feasibility for real-time procedural guidance. METHODS:In this retrospective multicenter study, 5,496 deidentified ICE cine loops from 249 procedures of unique patients, including routine clinical cases and the ViewFlex™ X first-in-human study, were analyzed. ICE experts classified each cine into 1 of 20 procedural views and annotated key anatomic structures, including the left atrium, left atrial appendage, pulmonary vein ostia, valves, cusps, papillary muscles, and left ventricle, at end-systole, and end-diastole, yielding 65,117 segmentations. A deep-learning segmentation model was trained using patient-level splits, standard augmentations, and early stopping. RESULTS:Segmentation performance was highest for larger cardiac chambers, with Dice scores of 0.94 for the left atrium and 0.82 for the left ventricle, and corresponding 95th-percentile Hausdorff distance values of 1.18 mm and 3.27 mm. Smaller structures also demonstrated acceptable performance, including the left atrial appendage, pulmonary veins, papillary muscles, and aortic cusps. The mean per-frame inference time was <0.03 seconds. CONCLUSIONS:Auto-Contour demonstrated robust multistructure segmentation of ICE anatomy with real-time inference, supporting prospective evaluation of artificial intelligence-assisted ICE for procedural standardization, efficiency, and safety.
PMID: 42296839
ISSN: 2772-963x
CID: 6049502